PMID- 30724573
OWN - NLM
STAT- MEDLINE
DCOM- 20200424
LR  - 20200424
IS  - 1557-8992 (Electronic)
IS  - 1044-5463 (Print)
IS  - 1044-5463 (Linking)
VI  - 29
IP  - 2
DP  - 2019 Mar
TI  - Rating of the Effectiveness of 26 Psychiatric and Seizure Medications for Autism 
      Spectrum Disorder: Results of a National Survey.
PG  - 107-123
LID - 10.1089/cap.2018.0121 [doi]
AB  - OBJECTIVE: The objective of this study was to provide an evaluation of the 
      benefits and adverse effects (AEs) of psychiatric and seizure medications 
      commonly used for individuals with autism spectrum disorder (ASD). METHODS: As 
      part of the National Survey on Treatment Effectiveness for Autism, we report 
      ratings of 26 psychiatric and seizure medications by 505 participants. Each 
      medication was rated with a standardized scale for overall benefits, overall AEs, 
      and specific symptoms affected. The frequency of use and net perceived benefit 
      (overall benefit minus overall AE) are reported. RESULTS: Most medications were 
      rated as having a slightly greater benefit than AE. Six medications (lamotrigine, 
      oxcarbazepine, clonidine, guanfacine, buspirone, and sertraline) had benefit 
      ratings that were more than twice their adverse rating. Conversely, some 
      medications had slightly negative net benefit ratings (worse AEs than benefits on 
      average), including Adderall, Paroxetine, Quetiapine, Olanzapine, and Topiramate. 
      However, there were wide variations in individual ratings of benefit and AEs, 
      suggesting that clinical response to medications was highly variable, so these 
      scores simply represent averages. A ranking of the top medications (those with 
      the highest net perceived benefit) for each of 18 different symptoms is provided, 
      which may provide some clinical guidance as to which medications may be most 
      worth considering for a given symptom. A comparison of the survey results with 
      the results of clinical trials shows generally good agreement in terms of 
      medication benefits with some differences; in some cases the differences are 
      because the clinical trials did not assess all of the symptoms assessed by this 
      survey. CONCLUSIONS: It is hoped that physicians and their patients will find the 
      survey results useful in selecting the most promising medications for a given 
      symptom, and also for monitoring for likely benefits and AEs, especially for 
      medications for which few or no studies have been carried out in ASD populations.
FAU - Coleman, Devon M
AU  - Coleman DM
AD  - 1 Arizona State University, Autism/Asperger's Research Program, Tempe, Arizona.
FAU - Adams, James B
AU  - Adams JB
AD  - 1 Arizona State University, Autism/Asperger's Research Program, Tempe, Arizona.
FAU - Anderson, Amy L
AU  - Anderson AL
AD  - 1 Arizona State University, Autism/Asperger's Research Program, Tempe, Arizona.
FAU - Frye, Richard E
AU  - Frye RE
AD  - 2 Barrow Neurological Institute, Phoenix Children's Hospital, Phoenix, Arizona.
LA  - eng
PT  - Journal Article
DEP - 20190206
PL  - United States
TA  - J Child Adolesc Psychopharmacol
JT  - Journal of child and adolescent psychopharmacology
JID - 9105358
RN  - 0 (Anticonvulsants)
RN  - 0 (Psychotropic Drugs)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anticonvulsants/adverse effects/*therapeutic use
MH  - Autism Spectrum Disorder/*drug therapy
MH  - Child
MH  - Female
MH  - Humans
MH  - Male
MH  - Psychotropic Drugs/adverse effects/*therapeutic use
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC6442266
OTO - NOTNLM
OT  - autism spectrum disorders
OT  - medications
OT  - online survey
OT  - psychiatric medications
OT  - seizure medications
EDAT- 2019/02/07 06:00
MHDA- 2020/04/25 06:00
PMCR- 2019/03/06
CRDT- 2019/02/07 06:00
PHST- 2019/02/07 06:00 [pubmed]
PHST- 2020/04/25 06:00 [medline]
PHST- 2019/02/07 06:00 [entrez]
PHST- 2019/03/06 00:00 [pmc-release]
AID - 10.1089/cap.2018.0121 [pii]
AID - 10.1089/cap.2018.0121 [doi]
PST - ppublish
SO  - J Child Adolesc Psychopharmacol. 2019 Mar;29(2):107-123. doi: 
      10.1089/cap.2018.0121. Epub 2019 Feb 6.